Company intelligence / Profile preview

NeuroSpa TMS

Tampa, Florida, United States

Ownership: Private
Development stage: Other

Overview

NeuroSpa TMS operates a network of revenue-generating outpatient mental health clinics delivering FDA-approved TMS, ketamine (IV), and Spravato® therapies for treatment-resistant depression, anxiety, suicidality, and related conditions, with published outcomes showing 80%+ sustained improvement for TMS and 70%+ sustained response for ketamine[2][4].

Therapeutic areas: Psychiatry
Modalities: DeviceSmall molecule
Industry: Non-Academic Healthcare

Partnerships

NRx Pharmaceuticals (pending/acquisition by its subsidiary HOPE Therapeutics)[2]

Beyond the preview

Go deeper on NeuroSpa TMS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroSpa TMS.

Explore the full profile